ArticleTranslational cancer research2025
Clinical efficacy and safety of pyrotinib as the first-line treatment of HER2-positive advanced breast cancer in Xinjiang Uygur Autonomous Region of China.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is a common malignant tumor posing a serious threat to women's health, with persistently high incidence and mortality rates. Among its subtypes, human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly invasive, prone to recurrence, and associated with a poorer prognosis. The aim of this study was to evaluate the real-world efficacy and safety of pyrotinib in the treatment of HER2-positive advanced breast cancer in the Xinjiang Uygur Autonomous Region of China. Methods: A total of 81 patients with HER2-positive advanced breast cancer who received first-line treatment of pyrotinib in the Affiliated Tumor Hospital of Xinjiang Medical University from May 2019 to January 2024 were included in this study. The patients' progression-free survival (PFS), objective response rate (ORR), and drug-related adverse events (AEs) were retrospectively analyzed and evaluated. Results: The median PFS (mPFS) of the patients was 20.5 months [95% confidence interval (CI): 18.98-22.02], and the median overall survival (OS) was not reached. The mPFS of the patients without brain metastases was 20.7 months (95% CI: 19.18-22.21), the mPFS of the patients with untreated or active brain metastases was 22.0 months (95% CI: 18.56-25.43), and the mPFS of patients with treated and stable brain metastases was 11.1 months (95% CI: 9.06-13.14). The differences between the three groups were statistically significant (P<0.001). The mPFS of the patients with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 was 21.0 months (95% CI: 20.31-21.69), whereas for those with a score of 1 or higher, it was 13.1 months (95% CI: 11.37-14.83), representing a statistically significant difference (P=0.002). The main AE was diarrhea, with an incidence of 71.6% (58/81), with grade 1 accounting for 34.6% (28/81), grade 2 for 27.2% (22/81), and grade 3 for 9.9% (8/81). No grade 4 diarrhea was observed. Conclusions: Pyrotinib showed good antitumor activity in the treatment of patients with HER2-positive advanced breast cancer and displayed a degree of efficacy in patients with brain metastases. The main adverse reaction was diarrhea, which was mostly low to moderate in severity, and the incidence of high-grade AEs was generally low, with controllable toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.